New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Abstract
IL13Ra2 is an attractive target due to its overexpression in a variety of cancers and rare expression in healthy tissue, motivating expansion of interleukin 13 (IL13)-based chimeric antigen receptor (CAR) T cell therapy from glioblastoma into systemic malignancies. IL13Ra1, the other binding partner of IL13, is ubiquitously expressed in healthy tissue, raising concerns about the therapeutic window of systemic administration. IL13 mutants with diminished binding affinity to IL13Ra1 were previously generated by structure-guided protein engineering. In this study, two such variants, termed C4 and D7, are characterized for their ability to mediate IL13Ra2-specific response as binding domains for CAR T cells. Despite IL13Ra1 and IL13Ra2 sharing similar binding interfaces on IL13, mutations to IL13 that decrease binding affinity for IL13Ra1 did not drastically change binding affinity for IL13Ra2. Micromolar affinity to IL13Ra1 was sufficient to pacify IL13-mutein CAR T cells in the presence of IL13Ra1-overexpressing cells in vitro. Interestingly, effector activity of D7 CAR T cells, but not C4 CAR T cells, was demonstrated when cocultured with IL13Ra1/IL4Ra-coexpressing cancer cells. While low-affinity interactions with IL13Ra1 did not result in observable toxicities in mice, in vivo biodistribution studies demonstrated that C4 and D7 CAR T cells were better able to traffic away from IL13Ra1+ lung tissue than were wild-type (WT) CAR T cells. These results demonstrate the utility of structure-guided engineering of ligand-based binding domains with appropriate selectivity while validating IL13-mutein CARs with improved selectivity for application to systemic IL13Ra2-expressing malignancies.
View details for DOI 10.1073/pnas.2112006119
View details for PubMedID 35939683